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Background: C4.4A is a highly glycosylated GPI-anchor protein
with some similarity to uPAR. Unlike uPAR, C4.4A has a very
restricted expression pattern. In normal tissues, expression of
C4.4A is limited to epithelia of skin, oesophagus and tongue.
RNA analysis revealed expression of human C4.4A in different
types of cancer including primary melanoma, lymph nodes and
skin metastases of melanoma, mammary gland cancer, lung car-
cinoma and lung tumour derived metastases, transitional cell
carcinoma (TCC) of urothelial cell origin and TCC derived
metastases.
Results: We produced antibodies against human C4.4A. In nor-
mal skin, C4.4A expression is limited only to the keratinocytes
of the stratum granulosum, while in wounded skin (chronic
ulcers), expression is extended also to the stratum spinosum.
C4.4A is expressed by different cancer cell lines including pan-
creas, prostate and breast cancer cell lines. Glycosylation of the
protein changes between different cell lines. Expression analysis
of C4.4A on cancer tissues specimens is ongoing. Preliminary
analysis shows over-expression of C4.4A in liver metastasis of
colon cancer origin.
The C4.4A homologue uPAR is released from cancer cell lines
and is present in the sera of cancer patients. Similarly, C4.4A is
released as whole molecule and fragments in the supernatant
of cancer cell lines.
Conclusion: These data indicate clinical relevance of the C4.4A
protein as a new diagnostic and possibly prognostic tumour
marker.1359-6349/$ - see front matter  2006 Published by Elsevier Ltd.
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PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) IN
PANCREATIC CANCER
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Background: Pancreatic cancer has a bad prognosis with an over-
all 5 year survival rate of less than 3% for all patients. The uroki-
nase-type plasminogen activator system plays a crucial role in
tumor invasion and angiogenesis. We analyzed the mRNA expres-
sion of urokinase-type plasminogen activator uPA, its receptor
uPAR and its inhibitor PAI-1 in pancreatic cancer.
Methods: Twenty-five tumor and corresponding normal tissue
samples from patients with pancreatic cancer were analyzed.
mRNA expression levels of uPA, uPAR and PAI-1 were detected
using quantitative realtime RT-PCR analysis; b-actin was used as
internal standard. Gene expression levels in tumor (T) and normal
tissue (N) were both expressed as absolute and relative measure-
ment values (T/N).
Results: Gene expressions of uPA and uPAR showed no signifi-
cant difference in tumor and normal tissue. However, expression
of PAI-1 mRNA was significantly (p < 0.006) lower in tumor (med-
ian 0.07, minimum 0, maximum 13.27) compared to normal tissue
(median 0.14, minimum 0.04, maximum 20.32). There was no sig-
nificant association with pT-, pN-category and grading.
Conclusion: In pancreatic cancer there is a significant down-
regulation of urokinase-type plasminogen activator inhibitor
(PAI-1).
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